Drug Approval | July 01, 2022
Zydus receives final approval from USFDA for Lacosamide injection
Lacosamide Injection is used to treat partial-onset seizures.
Lacosamide Injection is used to treat partial-onset seizures.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
The rally attracted around 250 riders, including professionals and amateurs.
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The cloud-based platform enables long-term brain monitoring towards personalized treatment
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Subscribe To Our Newsletter & Stay Updated
